Table 1 Baseline characteristics of analyzed cohort dichotomized by ADAM12 levels
Characteristics | Â | ADAM12 low | ADAM12 high | P-value |
|---|---|---|---|---|
|  |  | (n = 74) | (n = 161) |  |
Mean age (SD) | Â | 64.22 (8.14) | 62.90 (9.14) | 0.288 |
Gender n (%) | male | 44 (59.5) | 101 (62.7) | 0.738 |
female | 30 (40.5) | 60 (37.3) | Â | |
WHO n (%) | 0 | 62 (83.8) | 104 (64.6) | 0.005 |
1 | 12 (16.2) | 56 (34.8) | Â | |
na | 0 (0.0) | 1 (0.6) | Â | |
Primary tumor location n (%) | left | 33 (44.6) | 65 (40.4) | 0.319 |
right | 16 (21.6) | 48 (29.8) | Â | |
rectum | 24 (32.4) | 41 (25.5) | Â | |
na | 1 (1.4) | 7 (4.3) | Â | |
Metastasis n (%) | synchronous | 22 (29.7) | 111 (68.9) | < 0.001 |
metachronous | 52 (70.3) | 50 (31.1) | Â | |
Prior adjuvant therapy n (%) | no | 59 (79.7) | 136 (84.5) | 0.414 |
yes | 15 (20.3) | 24 (14.9) | Â | |
na | 0 (0.0) | 1 (0.6) | Â | |
Microsatellite status n (%) | MSI | 70 (94.6) | 149 (92.5) | 0.607 |
MSS | 4 (5.4) | 10 (6.2) | Â | |
na | 0 (0.0) | 2 (1.2) | Â | |
KRAS n (%) | wild type | 40 (54.1) | 107 (66.5) | 0.093 |
mutant | 34 (45.9) | 54 (33.5) | Â | |
BRAF n (%) | wild type | 68 (91.9) | 144 (89.4) | 0.726 |
mutant | 6 (8.1) | 17 (10.6) | Â | |
Tumor buds n (%) | < 5 | 21 (28.4) | 37 (23.0) | 0.312 |
5+ | 40 (54.1) | 104 (64.6) | Â | |
na | 13 (17.6) | 20 (12.4) | Â |